The Many Possible Benefits of Natriuretic Peptides After Myocardial Infarction
- 1 August 2005
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 46 (2) , 271-272
- https://doi.org/10.1161/01.HYP.0000173423.75174.cd
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Role of Natriuretic Peptide Receptor Guanylyl Cyclase-A in Myocardial Infarction Evaluated Using Genetically Engineered MiceHypertension, 2005
- Aldosterone and end-organ damageCurrent Opinion in Nephrology and Hypertension, 2005
- Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart FailureJAMA, 2005
- The Cardiac Antihypertrophic Effects of Cyclic GMP-Generating Agents: An Experimental Framework for Novel Treatments of Left Ventricular RemodelingVascular Disease Prevention, 2005
- Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart FailureCirculation, 2005
- C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarctionJournal of the American College of Cardiology, 2005
- Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophyNature Medicine, 2005
- Natriuretic peptides and myocardial ischaemiaBasic Research in Cardiology, 2004
- Role of a selective aldosterone blocker in mice with chronic heart failureJournal of Cardiac Failure, 2004
- Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-κB activation and alleviates myocardial ischemia/reperfusion injuryJournal of Clinical Investigation, 2001